Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium DOI Open Access
Michael Goggins, Kasper A. Overbeek, Randall E. Brand

et al.

Gut, Journal Year: 2019, Volume and Issue: 69(1), P. 7 - 17

Published: Oct. 31, 2019

The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for management individuals with increased risk pancreatic cancer based on family history or germline mutation status (high-risk individuals).A modified Delphi approach was employed reach among a multidisciplinary group experts who voted statements. Consensus considered reached if ≥75% agreed disagreed.Consensus 55 main goals surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 cancer) remained unchanged. Experts that those familial risk, should start no earlier than age 50 10 years youngest relative cancer, but were split whether at 55. Germline ATM carriers one affected first-degree are now eligible surveillance. preferred tests endoscopic ultrasound MRI/magnetic retrograde cholangiopancreatography, how alternate these modalities. Annual is recommended absence concerning lesions. Main areas disagreement included be performed hereditary pancreatitis, indeterminate lesions.Pancreatic selected high-risk detect early precursors, research setting by teams centres appropriate expertise. Until more evidence supporting available, benefits, risks costs need additional evaluation.

Language: Английский

Strategies for Colorectal Cancer Screening DOI
Uri Ladabaum, Jason A. Dominitz, Charles J. Kahi

et al.

Gastroenterology, Journal Year: 2019, Volume and Issue: 158(2), P. 418 - 432

Published: Aug. 5, 2019

Language: Английский

Citations

523
Integrating genomic features for non-invasive early lung cancer detection DOI
Jacob J. Chabon, Emily G. Hamilton, David M. Kurtz

et al.

Nature, Journal Year: 2020, Volume and Issue: 580(7802), P. 245 - 251

Published: March 25, 2020

Language: Английский

Citations

522
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention DOI Open Access
Anne Marie Lennon, Adam H. Buchanan,

Isaac Kinde

et al.

Science, Journal Year: 2020, Volume and Issue: 369(6499)

Published: April 28, 2020

A real-time trial of a cancer blood test Cancers diagnosed early are often more responsive to treatment. Blood tests that detect molecular markers have successfully identified individuals already known the disease. Lennon et al. conducted an exploratory study closely reflects way in which such would be used future. They evaluated feasibility and safety incorporating multicancer into routine clinical care 10,000 women with no history cancer. Over 12-month period, detected 26 cancers different types. combination positron emission tomography–computed tomography (PET-CT) imaging led surgical removal nine these cancers. Use did not result large number futile follow-up procedures. Science , this issue p. eabb9601

Language: Английский

Citations

502
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment DOI Open Access
Laura D. Wood, Marcia I. Canto, Elizabeth M. Jaffee

et al.

Gastroenterology, Journal Year: 2022, Volume and Issue: 163(2), P. 386 - 402.e1

Published: April 7, 2022

Language: Английский

Citations

499
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium DOI Open Access
Michael Goggins, Kasper A. Overbeek, Randall E. Brand

et al.

Gut, Journal Year: 2019, Volume and Issue: 69(1), P. 7 - 17

Published: Oct. 31, 2019

The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for management individuals with increased risk pancreatic cancer based on family history or germline mutation status (high-risk individuals).A modified Delphi approach was employed reach among a multidisciplinary group experts who voted statements. Consensus considered reached if ≥75% agreed disagreed.Consensus 55 main goals surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 cancer) remained unchanged. Experts that those familial risk, should start no earlier than age 50 10 years youngest relative cancer, but were split whether at 55. Germline ATM carriers one affected first-degree are now eligible surveillance. preferred tests endoscopic ultrasound MRI/magnetic retrograde cholangiopancreatography, how alternate these modalities. Annual is recommended absence concerning lesions. Main areas disagreement included be performed hereditary pancreatitis, indeterminate lesions.Pancreatic selected high-risk detect early precursors, research setting by teams centres appropriate expertise. Until more evidence supporting available, benefits, risks costs need additional evaluation.

Language: Английский

Citations

496